<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014413</url>
  </required_header>
  <id_info>
    <org_study_id>FMT-Pilot</org_study_id>
    <nct_id>NCT04014413</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fecal Microbiota Transplantation</brief_title>
  <official_title>Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiota is critical to health and functions with a level of complexity comparable
      to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have
      been implicated in a number of disease states. Fecal microbiota transplantation (FMT),
      defined as infusion of feces from healthy donors to affected subjects, is a method to restore
      a balanced gut microbiota and has attracted great interest in recent years due to its
      efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not
      responding to standard therapies.

      Recent studies have suggested that dysbiosis is associated with a variety of disorders, and
      that FMT could be a useful treatment. Randomized controlled trial has been conducted in a
      number of disorders and shown positive results, including alcoholic hepatitis, Crohn's
      disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic
      encephalopathy and metabolic syndrome. Case series/reports and pilot studies has shown
      positive results in other disorders including Celiac disease, functional dyspepsia,
      constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic
      encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant
      Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection,
      radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA
      enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.

      Despite FMT appears to be relatively safe and efficacious in treating a wide range of
      disease, its safety and efficacy in a usual clinical setting is unknown. More data is
      required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a
      pilot study to investigate the efficacy and safety of FMT in a variety of
      dysbiosis-associated disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of FMT in treating dysbiosis-associated disorder will be assessed by number of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Any improvement or deterioration or recurrence of the underlying condition by clinical judgement of doctors</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>25</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Celiac Disease</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Functional Dysphonia</condition>
  <condition>Constipation</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <condition>Multidrug -Resistant Infection</condition>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Pseudo-Obstruction</condition>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <condition>Vancomycin Resistant Enterococci Infection</condition>
  <condition>Multiple Organ Dysfunction Syndrome</condition>
  <condition>Dysbiotic Bowel Syndrome</condition>
  <condition>MRSA Enteritis</condition>
  <condition>Pseudomembranous Enterocolitis</condition>
  <condition>Alopecia</condition>
  <condition>Autism</condition>
  <condition>Graft-versus-host Disease</condition>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <condition>Atopy or Allergy</condition>
  <condition>Liver Disease</condition>
  <condition>Alcohol Dependence</condition>
  <condition>Psoriatic Arthropathy</condition>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irritable bowel syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional dyspepsia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Constipation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metabolic disease (diabetes mellitus or obesity)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multidrug-resistant infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic encephalopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudo-obstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRE infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VRE infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple organ dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysbiotic bowel syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRSA enteritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudomembranous enteritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alopecia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Graft-versus-host disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic thrombocytopenic purpura</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopy or allergy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol dependence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic-associated diarrhea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplant will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Fecal microbiota transplantation</description>
    <arm_group_label>Alcohol dependence</arm_group_label>
    <arm_group_label>Alopecia</arm_group_label>
    <arm_group_label>Antibiotic-associated diarrhea</arm_group_label>
    <arm_group_label>Atopy or allergy</arm_group_label>
    <arm_group_label>Autism</arm_group_label>
    <arm_group_label>CRE infection</arm_group_label>
    <arm_group_label>Celiac disease</arm_group_label>
    <arm_group_label>Constipation</arm_group_label>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_label>Dysbiotic bowel syndrome</arm_group_label>
    <arm_group_label>Functional dyspepsia</arm_group_label>
    <arm_group_label>Graft-versus-host disease</arm_group_label>
    <arm_group_label>Hepatic encephalopathy</arm_group_label>
    <arm_group_label>Idiopathic thrombocytopenic purpura</arm_group_label>
    <arm_group_label>Irritable bowel syndrome</arm_group_label>
    <arm_group_label>Liver disease</arm_group_label>
    <arm_group_label>MRSA enteritis</arm_group_label>
    <arm_group_label>Metabolic disease (diabetes mellitus or obesity)</arm_group_label>
    <arm_group_label>Multidrug-resistant infection</arm_group_label>
    <arm_group_label>Multiple organ dysfunction</arm_group_label>
    <arm_group_label>Multiple sclerosis</arm_group_label>
    <arm_group_label>Pseudo-obstruction</arm_group_label>
    <arm_group_label>Pseudomembranous enteritis</arm_group_label>
    <arm_group_label>Ulcerative colitis</arm_group_label>
    <arm_group_label>VRE infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Confirmed diagnosis of any of the following diseases:

          -  Crohn's disease

          -  Ulcerative colitis

          -  Celiac disease

          -  Irritable bowel syndrome

          -  Functional dyspepsia

          -  Constipation

          -  Antibiotic-associated diarrhea or any antibiotic- associated complications/symptoms

          -  Metabolic syndrome such as diabetes mellitus and obesity

          -  Multidrug-resistant infection

          -  Hepatic encephalopathy

          -  Multiple sclerosis

          -  Pseudo-obstruction

          -  Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci
             (VRE) infection

          -  Multiple organ dysfunction

          -  Dysbiotic bowel syndrome

          -  MRSA enteritis

          -  Pseudomembranous enteritis

          -  Alopecia, autism

          -  Graft-versus-host disease

          -  Idiopathic thrombocytopenic purpura (ITP)

          -  Atopy or allergy

          -  Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic
             steatohepatitis (NASH)

          -  Alcohol dependence

          -  Psoriatic arthropathy that has suboptimal control of disease despite standard
             treatment.

        Exclusion Criteria:

          -  Known contraindication to all FMT infusion method such as nasoduodenal tube insertion,
             oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema

          -  Any conditions that may render the efficacy of FMT or at the discretion of the
             investigators

          -  Current pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siew Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kitty Cheung</last_name>
    <phone>+852 26373260</phone>
    <email>kittyccy@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Li</last_name>
    <phone>+852 26373260</phone>
    <email>amyli@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <state>Shatin</state>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013 Feb;108(2):177-85. doi: 10.1038/ajg.2012.450. Epub 2013 Jan 15. Review.</citation>
    <PMID>23318479</PMID>
  </reference>
  <reference>
    <citation>Philips CA, Pande A, Shasthry SM, Jamwal KD, Khillan V, Chandel SS, Kumar G, Sharma MK, Maiwall R, Jindal A, Choudhary A, Hussain MS, Sharma S, Sarin SK. Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study. Clin Gastroenterol Hepatol. 2017 Apr;15(4):600-602. doi: 10.1016/j.cgh.2016.10.029. Epub 2016 Nov 2. Review.</citation>
    <PMID>27816755</PMID>
  </reference>
  <reference>
    <citation>Yang Z, Wang X, Bu C. Fecal microbiota transplant for Crohn's disease: a prospective, randomized study in chinese population. United european gastroenterology journal. Conference: 25th united european gastroenterology week, UEG 2017. Spain. Volume 5, 2017:A112-a113</citation>
  </reference>
  <reference>
    <citation>Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4. Epub 2017 Feb 15.</citation>
    <PMID>28214091</PMID>
  </reference>
  <reference>
    <citation>Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D'Haens GR, Ponsioen CY. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015 Jul;149(1):110-118.e4. doi: 10.1053/j.gastro.2015.03.045. Epub 2015 Mar 30.</citation>
    <PMID>25836986</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Surette M, Wolfe M, et al. A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis. Gastroenterology 2014;1):S-159</citation>
  </reference>
  <reference>
    <citation>Costello SP, Waters O, Bryant RV, et al. Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mildmoderately active ulcerative colitis: A randomised controlled trial. Gastroenterology 2017;152 (5 Supplement 1):S198-S199</citation>
  </reference>
  <reference>
    <citation>Kirk KF, Kousgaard SJ, Nielsen HL, et al. Faecal transplant for the treatment of chronic pouchitis-A randomised, placebo-controlled, clinical trial. Colorectal Disease 2017;19 (Supplement 2):143</citation>
  </reference>
  <reference>
    <citation>Johnsen PH, Hilpusch F, Cavanagh JP, et al. Fecal transplantation in Irritable Bowel Syndrome (IBS): An RCT. Neurogastroenterology and Motility 2017;29 (Supplement 2):135.</citation>
  </reference>
  <reference>
    <citation>Holster S, Repsilber D, Brummer RJ, et al. Faecal microbiota transfer in irritable bowel syndrome-clinical outcomes of a randomised placebo-controlled trial. United European Gastroenterology Journal 2017;5 (5 Supplement 1):A155-A156.</citation>
  </reference>
  <reference>
    <citation>Holster S, Brummer RJ, Repsilber D, et al. Fecal microbiota transplantation in irritable bowel syndrome and a randomized placebo-controlled trial. Gastroenterology 2017;152 (5 Supplement 1):S101-S102.</citation>
  </reference>
  <reference>
    <citation>Holger Johnsen P, Mazzawi T, El-Salhy M, et al. Effect of faecal microbiota transplantation on the enteroendocrine cells of the colon in patients with Irritable Bowel Syndrome (IBS): Double blinded-placebo controlled study. Neurogastroenterology and Motility 2017;29 (Supplement 2):71.</citation>
  </reference>
  <reference>
    <citation>Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant using a precision medicine approach is safe, Associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy. Journal of Hepatology 2017;66:S49-S49.</citation>
  </reference>
  <reference>
    <citation>Mullish BH, McDonald JAK, Thursz MR, Marchesi JR. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017 Oct;66(4):1354-1355. doi: 10.1002/hep.29369. Epub 2017 Aug 26.</citation>
    <PMID>28714089</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Siew Chien NG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

